RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals"The first half of 2024 shows how the industry has learned to execute accretive deals in the face of persistent headwinds,” the PwC report’s authors concluded. “
"So what’s driving interest from buyers? The report’s authors pointed to “strong numbers of novel therapeutic approvals, alongside major strides in innovation.”
And ONCY's pelareorep fits both the accretive and novel therapeutic approval value points that Big Pharma says it wants to have in an acquisition deal.